Foghorn Therapeutics Inc.
For the period ended Aug 5, 2025. Filed Aug 5, 2025.
View on SEC.govAbout this filing
A notice of a major event between regular reports, such as results, a deal or a change of executives. It is often the first formal record of the news.
Aug 5, 2025 · Filed Aug 5, 2025
Use the contents to explore the available documents and sections.
Contents
EX-99.1 · •Program update expected in Q4 2025
Program update expected in Q4 2025.
Selective ARID1B degrader program. Foghorn's Selective ARID1B degrader selectively targets and degrades ARID1B in ARID1A-mutated cancers. ARID1A is the most mutated subunit in the BAF complex and amongst the most mutated proteins in cancer. These mutations lead to a dependency on ARID1B in several types of cancer, including ovarian, endometrial, colorectal, and bladder. Attempts to selectively drug ARID1B have been challenging because of the high degree of similarity between ARID1A and ARID1B and the fact that ARID1B has no enzymatic activity to target. ARID1B is a major synthetic lethal target implicated in up to 5% of all solid tumors.
Developed highly potent and selective binders. Preclinical data demonstrated potent and selective small molecule binders to ARID1B.
Selective degradation of ARID1B achieved. Foghorn has successfully selectively degraded ARID1B.
Program update expected in Q4 2025.
Chromatin Biology and Degrader Platform. Foghorn continues to advance its chromatin biology and degrader platform with investments in novel ligases, long-acting injectables, oral delivery, and induced proximity.
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.